Torthaí cuardaigh - Christine A. Pratilas
- 1 - 20 toradh as 39 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response de réir Christine A. Pratilas, David B. Solit
Foilsithe / Cruthaithe 2010Revisão -
2
Targeting Oncogenic BRAF in Human Cancer de réir Christine A. Pratilas, Feng Xing, David B. Solit
Foilsithe / Cruthaithe 2010Artigo -
3
From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor de réir Kathryn M. Lemberg, Jiawan Wang, Christine A. Pratilas
Foilsithe / Cruthaithe 2020Revisão -
4
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors de réir Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas
Foilsithe / Cruthaithe 2019Revisão -
5
<sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway de réir Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen
Foilsithe / Cruthaithe 2009Artigo -
6
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance de réir Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, Gary K. Schwartz
Foilsithe / Cruthaithe 2012Artigo -
7
Models from experiments: combinatorial drug perturbations of cancer cells de réir Sven Nelander, Weiqing Wang, Bengt‐Olof Nilsson, Qing‐Bai She, Christine A. Pratilas, Neal Rosen, Peter Gennemark, Chris Sander
Foilsithe / Cruthaithe 2008Artigo -
8
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors de réir Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodríguez, Christine A. Pratilas
Foilsithe / Cruthaithe 2020Artigo -
9
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults de réir Karisa C. Schreck, Pinky Langat, Varun Bhave, Taibo Li, E. L. Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi
Foilsithe / Cruthaithe 2023Artigo -
10
Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat de réir Erin E. Resch, Stavriani C. Makri, Paola Ghanem, Ezra Baraban, Kenneth J. Cohen, Alan R. Cohen, Evan J. Lipson, Christine A. Pratilas
Foilsithe / Cruthaithe 2025Artigo -
11
BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines de réir Rébecca Leboeuf, Jacqueline E. Baumgartner, Miriam Benezra, Roberta Malaguarnera, David B. Solit, Christine A. Pratilas, Neal Rosen, Jeffrey A. Knauf, James A. Fagin
Foilsithe / Cruthaithe 2008Artigo -
12
3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition de réir David B. Solit, Elmer Santos, Christine A. Pratilas, Jose Lobo, Maxim A. Moroz, Shangde Cai, Ronald Blasberg, Judith S. Sebolt‐Leopold, Steven M. Larson, Neal Rosen
Foilsithe / Cruthaithe 2007Artigo -
13
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer de réir Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne
Foilsithe / Cruthaithe 2015Artigo -
14
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies de réir J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small
Foilsithe / Cruthaithe 2017Artigo -
15
Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases de réir Josephine K. Dermawan, Faizan Malik, John Gross, Ezra Baraban, Christine A. Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G. Barr, Felipe D’Almeida Costa, Karen Fritchie
Foilsithe / Cruthaithe 2024Artigo -
16
Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells de réir Anil Korkut, Weiqing Wang, Emek Demir, Bülent Arman Aksoy, Xiaohong Jing, Evan Molinelli, Özgün Babur, Debra L. Bemis, S. Onur Sumer, David B. Solit, Christine A. Pratilas, Chris Sander
Foilsithe / Cruthaithe 2015Artigo -
17
Size-based detection of sarcoma circulating tumor cells and cell clusters de réir Masanori Hayashi, Peixuan Zhu, Gregory McCarty, Christian F. Meyer, Christine A. Pratilas, Adam S. Levin, Carol D. Morris, Catherine M. Albert, Kyle W. Jackson, Cha-Mei Tang, David M. Loeb
Foilsithe / Cruthaithe 2017Artigo -
18
Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations de réir Doreen N. Palsgrove, Yunjie Li, Christine A. Pratilas, Ming‐Tseh Lin, Aparna Pallavajjalla, Christopher D. Gocke, Angelo M. De Marzo, Andrés Matoso, George J. Netto, Jonathan I. Epstein, Pedram Argani
Foilsithe / Cruthaithe 2018Artigo -
19
BRAF mutation predicts sensitivity to MEK inhibition de réir David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith S. Sebolt‐Leopold, William R. Sellers, Neal Rosen
Foilsithe / Cruthaithe 2005Artigo -
20
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner de réir Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen
Foilsithe / Cruthaithe 2010Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Biology
Cancer research
Medicine
Gene
Genetics
Cancer
MAPK/ERK pathway
Cell biology
Kinase
Internal medicine
Signal transduction
Mutation
MEK inhibitor
Oncology
Biochemistry
Melanoma
Pathology
KRAS
Mutant
Bioinformatics
Immunology
Lung cancer
Pharmacology
V600E
Chemistry
Colorectal cancer
Computational biology
Computer science
Metastatic melanoma
PI3K/AKT/mTOR pathway